• Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

    Source: Nasdaq GlobeNewswire / 09 May 2023 08:00:01   America/New_York

    WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the Piper Sandler Spring Biopharma Symposium being held from Wednesday, May 17 through Thursday, May 18, 2023 at the Encore Boston Harbor in Boston, MA.

    About Replimune
    Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

    Investor Inquiries
    Chris Brinzey
    ICR Westwicke
    339.970.2843
    chris.brinzey@westwicke.com

    Media Inquiries
    Lissette Steele
    Verge Scientific Communications
    202.930.4762 x 409
    lsteele@vergescientific.com


Share on,